Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Aria F. Olumi, M.D.

Title
Institution
Department
Address
Phone

Mentoring
current student opportunities
Available: 10/01/20, Expires: 05/30/26

Over 90% of adult males develop lower urinary tract symptoms (LUTS) secondary to bladder outlet obstruction by age 80, rendering benign prostatic hyperplasia (BPH) the most common proliferative abnormality in humans. BPH negatively impact the quality of life of 210 million men globally, accounting for significant life years lost, and costing the US healthcare system >$4 billion per year. Medical therapy for BPH, which includes 5α reductase inhibitors (5ARI, i.e., finasteride) targets both stromal and epithelial cells in the prostate gland. 5ARI’s are the only class of BPH-related drugs that reduces prostate size for the alleviation of LUTS. However, 34% of BPH patients do not respond to treatment and resistance to 5ARI therapy is a major limiting factor for effective management of BPH. It is not yet possible to predict responders vs. non-responders to 5ARI therapy, which creates a significant gap in our ability to effectively manage these patients. Finasteride, the most commonly prescribed 5ARI, is an inhibitor of steroid reductase 5α-2 (SRD5A2; also known as: 5-alpha reductase type 2 (5-AR2)), which is encoded by the gene SRD5A2. This proposal is based on the premise that epigenetic changes to SRD5A2 account for the significant number of patients who are unresponsive to 5ARI therapy. Here, we hypothesize that absence of SRD5A2 in human prostatic tissue, due to somatic methylation, is directly responsible for lack of sensitivity to 5ARI therapy in patients with BPH. Our goal is to assess SRD5A2 methylation and expression as a gene signature to predict which patients will respond to 5ARI therapy.

The student's role will be to explore the molecular and hormonal pathways and help develop a non-invasive radiologic signature to determine signatures of resistance to BPH-related therapies.

We have hosted students with varying degrees of experience and happy to consider any student who is motivated and excited about pursuing a scientific and clinically relevant question.


Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. R01DK124502 (OLUMI, ARIA F) May 1, 2020 - Mar 31, 2025
    NIH
    SRD5A2 as a Marker of Resistance to 5ARI Therapy
    Role: Principal Investigator
  2. R13DK121565 (OLUMI, ARIA F) Mar 1, 2019 - Feb 29, 2020
    NIH
    2019 AUA-SBUR BASIC SCIENCES SYMPOSIUM SOCIAL (AND ANTISOCIAL) CELL SIGNALING NETWORKS IN THE URINARY TRACT
    Role: Principal Investigator
  3. R01DK091353 (OLUMI, ARIA F.) Sep 15, 2011 - Apr 30, 2018
    NIH
    Reduced Levels of 5-alpha Reductase 2 in Adult Prostate Tissue and BPH Therapy
    Role: Principal Investigator
  4. K08DK064062 (OLUMI, ARIA F) Jul 1, 2003 - Jun 30, 2008
    NIH
    Stromal-Epithelial Interactions in Development of BPH
    Role: Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Garnick MB, Olumi A. EDITORIAL COMMENT. Urology. 2021 Sep; 155:31-32. PMID: 34489003.
    Citations:    Fields:    
  2. Wang Z, Cheng Z, Cristofaro V, Li J, Xiao X, Gomez P, Ge R, Gong E, Strle K, Sullivan MP, Adam RM, White MF, Olumi AF. Erratum. Inhibition of TNF-a Improves the Bladder Dysfunction That Is Associated With Type 2 Diabetes. Diabetes 2012;61:2134-2145. Diabetes. 2021 Jun; 70(6):1416. PMID: 33980694.
    Citations:    Fields:    
  3. Monfared S, Fleishman A, Korets R, Chang P, Wagner A, Bubley G, Kaplan I, Olumi AF, Gershman B. The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance. Urol Oncol. 2021 May 12. PMID: 33992521.
    Citations:    Fields:    
  4. Reitblat C, Fleishman A, Kaplan IA, Stensland KD, D'Amico AV, Olumi AF, Wagner AA, Chang PK, Kim SP, Korets R, Gershman B. Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial. Urol Oncol. 2021 Apr 29. PMID: 33934965.
    Citations:    Fields:    
  5. Tao Z, Shi L, Parke J, Zheng L, Gu W, Dong XC, Liu D, Wang Z, Olumi AF, Cheng Z. Sirt1 coordinates with ERa to regulate autophagy and adiposity. Cell Death Discov. 2021 Mar 15; 7(1):53. PMID: 33723227.
    Citations:    
  6. Unadkat P, Fleishman A, Olumi AF, Wagner A, Chang P, Kim SP, Korets R, Gershman B. Contemporary Incidence and Predictors of Occult Inguinal Lymph Node Metastases in Men With Clinically Node-negative (cN0) Penile Cancer. Urology. 2021 Jul; 153:221-227. PMID: 33636210.
    Citations: 1     Fields:    
  7. McConkey D, Best CJM, Gumminger JA, Olumi AF. "Advancing bladder preservation: Biomarkers, decision-making, and therapy". Urol Oncol. 2021 04; 39(4):199-200. PMID: 33487562.
    Citations:    Fields:    
  8. Wu S, Lin SX, Wirth GJ, Lu M, Lu J, Subtelny AO, Wang Z, Olumi AF, Dahl DM, Blute ML, Wu CL. Long-term Oncologic Impact of Positive Anterior and Posterior Surgical Margins After Radical Prostatectomy. Am J Clin Oncol. 2020 12 01; 43(12):872-879. PMID: 33002923.
    Citations:    Fields:    Translation:Humans
  9. Olumi AF. Editorial Comment. J Urol. 2020 10; 204(4):810. PMID: 32898979.
    Citations:    Fields:    Translation:Humans
  10. Unadkat P, Olumi AF, Gershman B. The Role of Lymphadenectomy in Patients with Advanced Renal Cell Carcinoma. Urol Clin North Am. 2020 Aug; 47(3):371-377. PMID: 32600538.
    Citations:    Fields:    Translation:Humans
  11. Zhang H, Frendl DM, Wang Z, Olumi AF. Reply by Authors. J Urol. 2020 08; 204(2):331. PMID: 32436767.
    Citations:    Fields:    
  12. Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, Vosoughi A, Fontugne J, Pan H, Lee D, Thomas D, Salari K, Wang Z, Romanel A, Te A, Lee R, Chughtai B, Olumi AF, Mosquera JM, Demichelis F, Elemento O, Rubin MA, Sboner A, Barbieri CE. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun. 2020 04 24; 11(1):1987. PMID: 32332823.
    Citations: 5     Fields:    Translation:HumansCells
  13. Zhang H, Frendl DM, Wang Z, Olumi AF. High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia. J Urol. 2020 Aug; 204(2):325-331. PMID: 32167867.
    Citations:    Fields:    Translation:Humans
  14. Wang Z, Deng T, Long X, Lin X, Wu S, Wang H, Ge R, Zhang Z, Wu CL, Taplin ME, Olumi AF. Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy. PLoS One. 2020; 15(3):e0229754. PMID: 32134978.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  15. Xue B, Wu S, Sharkey C, Tabatabaei S, Wu CL, Tao Z, Cheng Z, Strand D, Olumi AF, Wang Z. Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland. Prostate Cancer Prostatic Dis. 2020 09; 23(3):465-474. PMID: 32029929.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  16. Wu S, Lin X, Lin SX, Lu M, Deng T, Wang Z, Olumi AF, Dahl DM, Wang D, Blute ML, Wu CL. Impact of biopsy perineural invasion on the outcomes of patients who underwent radical prostatectomy: a systematic review and meta-analysis. Scand J Urol. 2019 Oct; 53(5):287-294. PMID: 31401922.
    Citations: 4     Fields:    Translation:Humans
  17. Wu S, Lin SX, Lu M, Subtelny AO, Wang Z, Dahl DM, Olumi AF, Wu CL. Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy. Int Urol Nephrol. 2019 Sep; 51(9):1527-1535. PMID: 31183659.
    Citations:    Fields:    Translation:Humans
  18. Burns RB, Olumi AF, Owens DK, Smetana GW. Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med. 2019 06 04; 170(11):770-778. PMID: 31158876.
    Citations: 1     Fields:    Translation:Humans
  19. Ingham MD, Lee RJ, MacDermed D, Olumi AF. Prostate cancer in transgender women. Urol Oncol. 2018 12; 36(12):518-525. PMID: 30322726.
    Citations: 4     Fields:    Translation:Humans
  20. Wu S, Lin SX, Wirth GJ, Lu M, Lu J, Subtelny AO, Wang Z, Dahl DM, Olumi AF, Wu CL. Impact of Multifocality and Multilocation of Positive Surgical Margin After Radical Prostatectomy on Predicting Oncological Outcome. Clin Genitourin Cancer. 2019 Feb; 17(1):e44-e52. PMID: 30287224.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  21. Yun H, Bedolla R, Horning A, Li R, Chiang HC, Huang TH, Reddick R, Olumi AF, Ghosh R, Kumar AP. BRCA1 Interacting Protein COBRA1 Facilitates Adaptation to Castrate-Resistant Growth Conditions. Int J Mol Sci. 2018 Jul 20; 19(7). PMID: 30036938.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  22. Vandergrift LA, Decelle EA, Kurth J, Wu S, Fuss TL, DeFeo EM, Halpern EF, Taupitz M, McDougal WS, Olumi AF, Wu CL, Cheng LL. Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue. Sci Rep. 2018 03 26; 8(1):4997. PMID: 29581441.
    Citations: 9     Fields:    Translation:Humans
  23. Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. Oncogene. 2018 05; 37(21):2793-2805. PMID: 29511347.
    Citations: 12     Fields:    Translation:HumansCells
  24. Tao Z, Zheng LD, Smith C, Luo J, Robinson A, Almeida FA, Wang Z, Olumi AF, Liu D, Cheng Z. Estradiol signaling mediates gender difference in visceral adiposity via autophagy. Cell Death Dis. 2018 02 22; 9(3):309. PMID: 29472585.
    Citations: 7     Fields:    Translation:AnimalsCells
  25. Wu S, Ye J, Wang Z, Lin SX, Lu M, Liang Y, Zhu X, Olumi AF, Zhong WD, Wu CL. Expression of aromatase in tumor related stroma is associated with human bladder cancer progression. Cancer Biol Ther. 2018 03 04; 19(3):175-180. PMID: 29303414.
    Citations: 4     Fields:    Translation:Humans
  26. Wang Z, Hu L, Salari K, Bechis SK, Ge R, Wu S, Rassoulian C, Pham J, Wu CL, Tabatabaei S, Strand DW, Olumi AF. Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5a-reductase 2. J Pathol. 2017 12; 243(4):457-467. PMID: 28940538.
    Citations: 8     Fields:    Translation:HumansCells
  27. Wang Z, Olumi AF. Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease? Am J Physiol Renal Physiol. 2018 03 01; 314(3):F407-F411. PMID: 29117997.
    Citations:    Fields:    Translation:HumansAnimalsCells
  28. Rodin D, Drumm M, Clayman R, Buscariollo DL, Galland-Girodet S, Eidelman A, Feldman AS, Dahl DM, McGovern FJ, Olumi AF, Niemierko A, Shipley WU, Zietman AL, Efstathiou JA. Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience. Clin Genitourin Cancer. 2017 Aug 03. PMID: 28864223.
    Citations: 2     Fields:    
  29. Frendl DM, Olumi AF. Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer. Cancer. 2017 09 15; 123(18):3447-3449. PMID: 28542736.
    Citations:    Fields:    Translation:Humans
  30. Wang Z, Xiao X, Ge R, Li J, Johnson CW, Rassoulian C, Olumi AF. Metformin inhibits the proliferation of benign prostatic epithelial cells. PLoS One. 2017; 12(3):e0173335. PMID: 28253329.
    Citations: 7     Fields:    Translation:HumansCells
  31. Ge R, Wang Z, Wu S, Zhuo Y, Otsetov AG, Cai C, Zhong W, Wu CL, Olumi AF. Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells. Oncotarget. 2015 Oct 06; 6(30):28973-87. PMID: 26359363.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  32. Yun H, Xie J, Olumi AF, Ghosh R, Kumar AP. Activation of AKR1C1/ERß induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity. Oncotarget. 2015 May 10; 6(13):11600-13. PMID: 25816367.
    Citations: 13     Fields:    Translation:HumansCells
  33. Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, Tabatabaei S, Olumi AF. Age and Obesity Promote Methylation and Suppression of 5a-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia. J Urol. 2015 Oct; 194(4):1031-7. PMID: 25916673.
    Citations: 10     Fields:    Translation:HumansCells
  34. Cornejo KM, Lu M, Yang P, Wu S, Cai C, Zhong WD, Olumi A, Young RH, Wu CL. Succinate dehydrogenase B: a new prognostic biomarker in clear cell renal cell carcinoma. Hum Pathol. 2015 Jun; 46(6):820-6. PMID: 25827535.
    Citations: 8     Fields:    Translation:Humans
  35. Ge R, Wang Z, Bechis SK, Otsetov AG, Hua S, Wu S, Wu CL, Tabatabaei S, Olumi AF. DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. Am J Pathol. 2015 Mar; 185(3):870-82. PMID: 25700986.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  36. Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, Loda M, Giovannucci E, Mucci LA, Olumi AF. 5a-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014 Aug; 174(8):1301-7. PMID: 24887392.
    Citations: 10     Fields:    Translation:Humans
  37. Rodríguez D, Preston MA, Barrisford GW, Olumi AF, Feldman AS. Clinical features of leiomyosarcoma of the urinary bladder: analysis of 183 cases. Urol Oncol. 2014 Oct; 32(7):958-65. PMID: 25027684.
    Citations: 6     Fields:    Translation:Humans
  38. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, Sørensen HT. Metformin use and prostate cancer risk. Eur Urol. 2014 Dec; 66(6):1012-20. PMID: 24857538.
    Citations: 46     Fields:    Translation:Humans
  39. Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 2014 Jul; 192(1):16-23. PMID: 24582540.
    Citations: 31     Fields:    Translation:Humans
  40. Olumi AF. Commentary on "the E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity." Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA, Signal Transduction Program, Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA.: Cancer Cell 2013;23(6):332-46. Urol Oncol. 2014 Feb; 32(2):210-1. PMID: 24445292.
    Citations:    Fields:    Translation:HumansAnimalsCells
  41. Olumi AF. Commentary on "age-related alterations in T-lymphocytes modulate key pathways in prostate tumorigenesis." De Angulo A, Faris R, Cavazos D, Jolly C, Daniel B, DeGraffenried L, Department of Nutritional Sciences, Dell Pediatric Research Institute, University of Texas, Austin, TX, USA.: Prostate 2013;73(8):855-64 [Epub 2013 Mar 26]. Urol Oncol. 2014 Feb; 32(2):212-3. PMID: 24445295.
    Citations: 1     Fields:    Translation:AnimalsCells
  42. Olumi AF. Commentary on "identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array." Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS-Cancer Research UK GWAS-ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study Urol Oncol. 2014 Feb; 32(2):211. PMID: 24445293.
    Citations: 34     Fields:    Translation:Humans
  43. Olumi AF. Commentary on "ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients." Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, Mucci LA, Loda M, Yuan GC, Orkin SH, Li Z, Division of Hematology and Oncology, Boston Children's Hospital, Boston, MA, USA.: Genes Dev 2013;27(6):683-98. Urol Oncol. 2014 Feb; 32(2):213. PMID: 24445296.
    Citations: 1     Fields:    Translation:HumansAnimals
  44. Olumi AF. Commentary on "randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients." Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, Klotz L, Finelli A, Fleshner N, Vieth R, Department of Nutritional Sciences, University of Toronto, Ontario, Canada.: J Clin Endocrinol Metab 2013;98(4):1498-507 [Epub 2013 Mar 5]. Urol Oncol. 2014 Feb; 32(2):210. PMID: 24445291.
    Citations: 1     Fields:    Translation:Humans
  45. Olumi AF. Commentary on "integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer." Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T, Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.: Cancer Cell 2013;23(2):159-70. Urol Oncol. 2014 Feb; 32(2):212. PMID: 24445294.
    Citations: 11     Fields:    Translation:Humans
  46. Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA. Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract. 2014 Mar; 10(2):107-12. PMID: 24399853.
    Citations: 4     Fields:    Translation:Humans
  47. Xu R, Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD. Prognostic significance of indeterminate lung nodules in renal cell carcinoma. Urol Oncol. 2014 Apr; 32(3):355-61. PMID: 24397994.
    Citations: 3     Fields:    Translation:Humans
  48. Yang H, Chen X, Wang X, Li Y, Chen S, Qian X, Wang R, Chen L, Han W, Ruan A, Du Q, Olumi AF, Zhang X. Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation. Mol Cancer Res. 2014 Feb; 12(2):217-27. PMID: 24296757.
    Citations: 3     Fields:    Translation:HumansCells
  49. Rodríguez D, Barrisford GW, Sanchez A, Preston MA, Kreydin EI, Olumi AF. Primary spermatic cord tumors: disease characteristics, prognostic factors, and treatment outcomes. Urol Oncol. 2014 Jan; 32(1):52.e19-25. PMID: 24239475.
    Citations: 23     Fields:    Translation:Humans
  50. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72. PMID: 24225970.
    Citations: 4     Fields:    Translation:Humans
  51. Olumi AF, Kaufman DS, Zietman A, Harisinghani MG, Wu CL. Case records of the Massachusetts General Hospital. Case 25-2013. A 71-year-old man with hematuria and a mass in the bladder. N Engl J Med. 2013 Aug 15; 369(7):660-7. PMID: 23944304.
    Citations:    Fields:    Translation:Humans
  52. Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, Mayers JR, Schwab M, Bellinger G, Csibi A, Patnaik A, Blouin MJ, Cantley LC, Guarente L, Blenis J, Pollak MN, Olumi AF, Vander Heiden MG, Stephanopoulos G. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 2013 Jul 15; 73(14):4429-38. PMID: 23687346.
    Citations: 82     Fields:    Translation:AnimalsCells
  53. Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 2013 Mar 05; 17(3):372-85. PMID: 23473032.
    Citations: 134     Fields:    Translation:HumansAnimalsCells
  54. Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD. Prognostic significance of indeterminate lung nodules in renal cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6_suppl):377. PMID: 28136903.
    Citations:    
  55. Paly JJ, Zietman AL, Nguyen PL, Beard C, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55. PMID: 28137047.
    Citations:    
  56. Rodríguez D, Olumi AF. Management of spermatic cord tumors: a rare urologic malignancy. Ther Adv Urol. 2012 Dec; 4(6):325-34. PMID: 23205059.
    Citations: 20     
  57. Olumi AF. Editorial comment. J Urol. 2012 Dec; 188(6):2107. PMID: 23083855.
    Citations:    Fields:    Translation:HumansCells
  58. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6. PMID: 22851571.
    Citations: 41     Fields:    Translation:Humans
  59. Wang Z, Cheng Z, Cristofaro V, Li J, Xiao X, Gomez P, Ge R, Gong E, Strle K, Sullivan MP, Adam RM, White MF, Olumi AF. Inhibition of TNF-a improves the bladder dysfunction that is associated with type 2 diabetes. Diabetes. 2012 Aug; 61(8):2134-45. PMID: 22688336.
    Citations: 22     Fields:    Translation:AnimalsCells
  60. Dong F, Wang C, Farris AB, Wu S, Lee H, Olumi AF, McDougal WS, Young RH, Wu CL. Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system. Am J Surg Pathol. 2012 Jun; 36(6):838-43. PMID: 22592143.
    Citations: 21     Fields:    Translation:Humans
  61. Lu J, Wirth GJ, Wu S, Chen J, Dahl DM, Olumi AF, Young RH, McDougal WS, Wu CL. A close surgical margin after radical prostatectomy is an independent predictor of recurrence. J Urol. 2012 Jul; 188(1):91-7. PMID: 22578729.
    Citations: 8     Fields:    Translation:Humans
  62. Psutka SP, Olumi AF, Feldman AS, Saylor PJ, Kaufman DS, Lee RJ. Pathologic down-staging and complete pathologic response with gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder. J Clin Oncol. 2012 Feb 10; 30(5_suppl):307. PMID: 28143141.
    Citations:    
  63. Gershman B, Dahl DM, Olumi AF, Young RH, McDougal WS, Wu CL. Smaller prostate gland size and older age predict Gleason score upgrading. Urol Oncol. 2013 Oct; 31(7):1033-7. PMID: 22206627.
    Citations: 12     Fields:    Translation:Humans
  64. Wang Z, Olumi AF. Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation. 2011 Nov-Dec; 82(4-5):261-71. PMID: 21536370.
    Citations: 13     Fields:    Translation:HumansCells
  65. Psutka SP, Feldman AS, Rodin D, Olumi AF, Wu CL, McDougal WS. Men with organ-confined prostate cancer and positive surgical margins develop biochemical failure at a similar rate to men with extracapsular extension. Urology. 2011 Jul; 78(1):121-5. PMID: 21411125.
    Citations: 6     Fields:    Translation:Humans
  66. Niu Y, Ge R, Hu L, Diaz C, Wang Z, Wu CL, Olumi AF. Reduced levels of 5-a reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate. 2011 Sep; 71(12):1317-24. PMID: 21308715.
    Citations: 21     Fields:    Translation:HumansCells
  67. Ge R, Wang Z, Zeng Q, Xu X, Olumi AF. F-box protein 10, an NF-?B-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway. Cell Death Differ. 2011 Jul; 18(7):1184-95. PMID: 21252908.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  68. Zhang X*, Huang X*, Olumi AF (*contributed equally). Repression of NF-kB and Activation of AP-1 Enhance Apoptosis in Prostate Cancer Cells. International Journal of Cancer. 2009; 124(8):1980-9.
  69. Zhang X, Huang X, Olumi AF. Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells. Int J Cancer. 2009 Apr 15; 124(8):1980-9. PMID: 19123467.
    Citations: 8     Fields:    Translation:HumansCells
  70. Olumi AF, Dewolf WC. The hybrid of basic science and clinical training for the urologic oncologist: Necessity or waste? Urol Oncol. 2009 Mar-Apr; 27(2):205-7. PMID: 19285235.
    Citations: 1     Fields:    Translation:Humans
  71. Ganapathy M, Ghosh R, Jianping X, Zhang X, Bedolla R, Schoolfield J, Yeh IT, Troyer DA, Olumi AF, Kumar AP. Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res. 2009 Mar 01; 15(5):1601-11. PMID: 19223508.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  72. Pedrosa I, Sun MR, Spencer M, Genega EM, Olumi AF, Dewolf WC, Rofsky NM. MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics. 2008 Jul-Aug; 28(4):985-1003. PMID: 18635625.
    Citations: 60     Fields:    Translation:Humans
  73. Zhang X, Li W, Olumi AF. Overcoming resistance to trail-induced apoptosis in prostate cancer by regulation of c-FLIP. Methods Enzymol. 2008; 446:333-49. PMID: 18603132.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  74. Zhang X, Huang X, Olumi AF. Repression of NF-ƒÛB and Activation of AP-1 Enhance Apoptosis in Prostate Cancer Cells. American Assc of Cancer Research Annual Meeting. 2008.
  75. Olumi AF, Richie JP. Urologic Surgery. Sabiston’s Textbook of Surgery – the biological basis of modern surgical practice. In: Townsend CM, Beauchamp RD, Evers BM, Mattox KL, editors. 2008; 18:2251-2286.
  76. Huang X, Zhang X, Olumi AF. c-FLIP’s Alternative Transcriptional Start Sites Differentially Regulate Sensitivity to TRAIL-induced Apoptosis in Prostate Cancer Cells. American Assc Cancer Research Annual Meeting. 2008.
  77. Huang X, Zhang X, Olumi AF. c-FLIP’s Alternative Transcriptional Start Sites Differentially Regulate Sensitivity to TRAIL-induced Apoptosis in Prostate Cancer Cells. American Urological Assc Annual Meeting. 2008.
  78. Zhang X, Li W, Olumi AF. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells. Clin Cancer Res. 2007 Dec 01; 13(23):7181-90. PMID: 18056199.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  79. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X, Zhang L, Kim WY, Olumi AF, Kaelin WG. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell. 2007 Oct 12; 28(1):15-27. PMID: 17936701.
    Citations: 75     Fields:    Translation:HumansAnimalsCells
  80. Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res. 2007 Oct 01; 67(19):9425-34. PMID: 17909052.
    Citations: 34     Fields:    Translation:HumansAnimalsCells
  81. Olumi AF. Workforce Needed: Urology Physician-Scientists. American Urological Association News. 2007; 12(10):1.
  82. Huang X, Zhang X, Farahvash B, Olumi AF. Novel targeted pro-apoptotic agents for the treatment of prostate cancer. J Urol. 2007 Nov; 178(5):1846-54. PMID: 17868738.
    Citations: 5     Fields:    Translation:HumansAnimals
  83. Li W, Wu CL, Febbo PG, Olumi AF. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol. 2007 Oct; 171(4):1189-98. PMID: 17702894.
    Citations: 24     Fields:    Translation:HumansCells
  84. Olumi AF. Editorial Comment. The impact factors on prognosis of pT3 patients with upper urinary tract transitional cell carcinoma. 2007; 178(2):450.
  85. Halperin TJ, Slavin SA, Olumi AF, Borud LJ. Surgical management of scrotal lymphedema using local flaps. Ann Plast Surg. 2007 Jul; 59(1):67-72; discussion 72. PMID: 17589264.
    Citations: 5     Fields:    Translation:Humans
  86. Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, Mao M, Bartz S, Kaelin WG. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol. 2007 Aug; 27(15):5381-92. PMID: 17526729.
    Citations: 56     Fields:    Translation:HumansAnimalsCells
  87. Zhang X, Olumi AF . TPA enhances TRAIL-induced apoptosis in prostate cancer cells. American Association of Cancer Research Annual Meeting. 2007.
  88. Ganapathy M, Zhang X, Olumi AF, Ghosh R, Kumar AP . Anti-proliferative activity of 2-Methoxyestradiol (2-ME) in prostate cancer cells through induction of apoptosis . American Association of Cancer Research Annual Meeting. 2007.
  89. Li W, Zhang X, Olumi AF . MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L) . American Association of Cancer Research Annual Meeting. 2007.
  90. Li W, Febbo PG, Olumi AF . Stromally expressed c-Jun regulates proliferation of prostate epithelial cells . American Association of Cancer Research Annual Meeting. 2007.
  91. Li W, Zhang X, Olumi AF. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res. 2007 Mar 01; 67(5):2247-55. PMID: 17332355.
    Citations: 33     Fields:    Translation:HumansCells
  92. Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, Mao M, Bartz S, Kaelin WG Jr. HIF linked to differential kidney cancer risk seen with type 2a and type 2b VHL mutations. Molecular Cellular Biology. 2007; 27:5381-92.
  93. Yang H, Minamishima YA, Yan Q, Schlisio S, Zhang X, Zhang L, Kim WY, Olumi AF, Kaelin WG Jr. Novel adapter role for pVHL: Promoting inhibitory phosphorylation of the NF-kB agonist Card9 by CK2. Molecular Cell. 2007; 28:15-27.
  94. Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett. 2007 Jun 18; 251(1):146-57. PMID: 17184908.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  95. Adey GS, Genega EM, Pedrosa I, Olumi AF. . Upper urinary tract carcinoma: transitional or renal cell?. Issues in Urology. 2006; 18:234-8.
  96. Huang WY, Olumi AF, Rosen S. Urothelial mucosal malformation: a rare cause for ureteropelvic junction obstruction. Pediatr Dev Pathol. 2006 Jan-Feb; 9(1):72-4. PMID: 16808629.
    Citations: 1     Fields:    Translation:Humans
  97. San Francisco IF, Regan MM, Dewolf WC, Olumi AF. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol. 2006 Apr; 175(4):1341-5; discussion 1345-6. PMID: 16515994.
    Citations: 6     Fields:    Translation:Humans
  98. San Francisco IF, Regan, MM, DeWolf WC, Olumi AF . Low age-adjusted free-testosterone is associated with poorly differentiated prostate cancer. J Urol. 2006; 175(4):1341-5;discussion 1345-6.
  99. Manonmani G, Esparza J, Zhang X, Olumi AF, Ghosh R, Kumar AP. . 2-Methoxyestradiol Inhibits Proliferation and Induces Apoptosis through down regulation of FLIP. Cell Signaling Annual Meeting. 2006.
  100. Olumi AF, Editorial comment: . Tumor necrosis as prognostic indicator in transitional cell carcinoma of upper urinary tract. J Urol. 2006; 176:913-4.
  101. Zhang X, Huang X, Li W, Olumi AF. . Differentiating between TNF-alpha and TRAIL-induced apoptosis in prostate cancer cells. Society of Basic Urologic Research Annual Meeting. 2006.
  102. Zhang L, Zhang X, Barrisford G, Olumi AF. . Lexatumumab (TRAIL-Receptor 2 mAb) Induces Expression of DR5 and Promotes Apoptosis in Primary and Metastatic Renal Cell Carcinoma in a Mouse Orthotopic Model. Society of Basic Urologic Research Annual Meeting. 2006.
  103. Zhang X, Yang H, Zhang L, Otu H, Libermann, T, DeWolf WC, Khosravi-Far R, Olumi AF. . c-Fos promotes TRAIL-induced apoptosis by repressing c-FLIP(L). American Urological Association Meeting. 2006.
  104. Zhang L, Zhang X, Olumi AF. . Differentiating molecular differences between TRAIL-sensitive and TRAIL-resistant renal cell carcinoma cells. American Association Cancer Research Annual Meeting. 2005.
  105. Zhang X, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. . c-Fos nuclear translocation represses c-FLIP(L) and enhances TRAIL-induced apoptosis in prostate cancer cells. Cold Spring Harbor – Programmed Cell Death Meeting. Cold Spring Harbor. 2005.
  106. Olumi AF, San Francisco I. Editorial letter: Matrix Metalloproteinases activity and stromal-epithelial interactions. Int. J of Cancer. 2005; 655.
  107. Zhang X, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. . Increased expression of c-Fos/AP-1 is required for prostate cancer cells to undergo TRAIL mediated apoptosis. American Association Cancer Research Annual Meeting. 2005.
  108. Olumi AF, Editorial comment: . The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol. 2005; 174:1260-1.
  109. San Francisco IF, DeWolf WC, Peehl DM, Olumi AF. Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer. 2004 Nov 01; 112(2):213-8. PMID: 15352032.
    Citations: 20     Fields:    Translation:HumansCells
  110. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res. 2004 Oct 01; 64(19):7086-91. PMID: 15466204.
    Citations: 46     Fields:    Translation:HumansCells
  111. Kuten A, Olumi A, Goldsmith J, Monahan-Earley RA, Dvorak AM, Genega EM. Pathologic quiz case. A symptomatic renal tumor. Juxtaglomerular cell tumor. Arch Pathol Lab Med. 2004 Sep; 128(9):e112-4. PMID: 15335262.
    Citations: 1     Fields:    Translation:Humans
  112. Olumi AF. Self-retraction clamp for dissection of the posterior prostatic fossa during radical retropubic prostatectomy. ScientificWorldJournal. 2004 Jun 07; 4 Suppl 1:260-2. PMID: 15349550.
    Citations:    Fields:    Translation:Humans
  113. San Francisco IF, Regan MM, Olumi AF, DeWolf WC. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. J Urol. 2004 Apr; 171(4):1492-9. PMID: 15017206.
    Citations: 4     Fields:    Translation:Humans
  114. San Francisco IF, Regan, MM, DeWolf WC, Olumi AF. Hypogonadism is associated with lower prostate specific antigen, later diagnosis and poorly differentiated prostate cancer: implications for a lower screening threshold. American Urological Association Annual Meeting. 2004.
  115. San Francisco IF, Regan, MM, DeWolf WC, Olumi AF . Outcome of patients after radical retropubic prostatectomy: a comparison of prostate cancer diagnosed using extended needle biopsy technique versus non-extended needle biopsy technique. UroOncology. 2004; 4(2):85-90.
  116. San Francisco IF, DeWolf WC, Peehl DM, Olumi AF. . Expression of Transforming Growth Factor-Beta 1 and growth in soft agar differentiates between prostate carcinoma-associated fibroblasts from normal prostate fibroblasts in-vitro. American Association of Cancer Research Meeting. 2004.
  117. Zhang X, San Francisco IF, DeWolf WC, Jin T, Khosravi-Far R, Olumi AF. . Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Regulate Sensitivity to TRAIL-mediated Apoptosis in Prostate Cancer. American Association of Cancer Research Annual Meeting. 2004.
  118. Olumi AF, Richie JP. . Urologic Surgery. In: Townsend CM, Beauchamp RD, Evers BM, Mattox KL, editors. Sabiston’s Textbook of Surgery – the biological basis of modern surgical practice. 2004; 2283-2318.
  119. Zhang X, Jin T, Yang H, DeWolf WC, Jin T, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Regulate Sensitivity to TRAIL-mediated Apoptosis in Prostate Cancer. Cancer Res. 2004; 64(19):7086-91.
  120. San Francisco IF, Olumi AF, Yoon JH, Regan MM, DeWolf WC. Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and prostate-specific antigen failure after radical prostatectomy. BJU Int. 2003 Dec; 92(9):924-8. PMID: 14632848.
    Citations:    Fields:    Translation:Humans
  121. San Francisco IF, Olumi AF, Kao J, Rosen S, DeWolf WC. Clinical management of prostatic intraepithelial neoplasia as diagnosed by extended needle biopsies. BJU Int. 2003 Mar; 91(4):350-4. PMID: 12603413.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  122. San Francisco IF, DeWolf WC, Rosen S, Upton M, Olumi AF. Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol. 2003 Jan; 169(1):136-40. PMID: 12478121.
    Citations: 38     Fields:    Translation:Humans
  123. San Francisco IF, Olumi AF, Kao J, Rosen S, DeWolf WC. Clinical management of prostatic intraepithelial neoplasia as diagnosed by extended needle biopsies. British Journal of Urology. 2003; 91:350.
  124. Ung JO, San Francisco IF, Regan MM, DeWolf WC, Olumi AF. The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. J Urol. 2003 Jan; 169(1):130-5. PMID: 12478120.
    Citations: 20     Fields:    Translation:Humans
  125. San Francisco IF, Olumi AF, Yoon, JH, Regan, MM, DeWolf WC. Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and PSA failure after radical prostatectomy. British Journal of Urology. 2003; 92:924-8.
  126. Singh, D, Olumi AF. Evaluation of Hematuria In: Furie B, Cassileth P, Atkins MB, and Mayer R, editors. Clinical Hematology and Oncology: Presentation, Diagnosis and Treatment. Churchill Livingstone publishing. 2003.
  127. Olumi AF, Zhang X, San Francisco IF, DeWolf WC, Jin T, Khosravi-Far R. Protein expression of c-FLIP(L) is associated with resistance to trail-induced apoptosis in prostate cancer. American Urological Association Annual Meeting. 2003.
  128. San Francisco IF, Olumi AF, Jerry Kao, Seymour Rosen, DeWolf WC. . The natural history of prostatic intraepithelial neoplasia as defined by extended needle biopsies. American Urological Association Annual Meeting. 2002.
  129. Ung JO, San Francisco IF, Regan MM, DeWolf WC, Olumi AF. . Lower prostate cancer detection rate in large prostate glands is not associated with biopsy sampling error. American Urological Association Annual Meeting. 2002.
  130. Olumi AF, Xiao Y, San Francisco IF, Donna M. Peehl, DeWolf WC. Retroviral transfection of human telomerase gene more commonly leads to senescence than expansion of lifespan in prostate fibroblasts. American Urological Association Annual Meeting. 2002.
  131. Olumi AF. Book Review: Prostate Cancer: Biology, Genetics, and the New Therapeutics. New England Journal of Medicine. Edited by Leland W.K. Chung, William B. Isaacs, and Jonathan W. Simons. 2002; 1677-8.
  132. Olumi AF, Weidner N, Presti JC. p53 immunoreactivity correlates with Ki-67 and bcl-2 expression in renal cell carcinoma. Urol Oncol. 2001 Mar; 6(2):63-67. PMID: 11166623.
    Citations: 6     Fields:    
  133. Olumi AF, Weidner N, Presti JJr . p53 Immunoreactivity Correlates with Ki-67 and Bcl-2 Expression in Renal Cell Carcinoma. Urologic Oncology. 2001; 6:63-7.
  134. Olumi AF, Richie JP, Schultz DJ, D'Amico AV. Calculated volume of prostate cancer identifies patients with clinical stage T1C disease at high risk of biochemical recurrence after radical prostatectomy: a preliminary study. Urology. 2000 Aug 01; 56(2):273-7. PMID: 10925093.
    Citations: 4     Fields:    Translation:Humans
  135. Olumi AF. A critical analysis of the use of p53 as a marker for management of bladder cancer. Urol Clin North Am. 2000 Feb; 27(1):75-82, ix. PMID: 10696247.
    Citations: 4     Fields:    Translation:Humans
  136. Olumi AF . A critical use of p53 as a marker for management of bladder cancer. Urologic Clinics of North America. 2000; 27:75-82.
  137. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999 Oct 01; 59(19):5002-11. PMID: 10519415.
    Citations: 570     Fields:    Translation:HumansAnimalsCells
  138. Olumi AF, Richie JR. Surgical Treatment of Invasive Bladder Cancer In: Syrigos KN and Skinner DG, editors. Bladder cancer: biology, diagnosis and management. Oxford Univ. Press. 1999.
  139. Olumi AF, Dazin P, Tlsty TD. A novel coculture technique demonstrates that normal human prostatic fibroblasts contribute to tumor formation of LNCaP cells by retarding cell death. Cancer Res. 1998 Oct 15; 58(20):4525-30. PMID: 9788594.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  140. Grossfeld GD, Olumi AF, Connolly JA, Chew K, Gibney J, Bhargava V, Waldman FM, Carroll PR. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol. 1998 May; 159(5):1437-43. PMID: 9554329.
    Citations: 15     Fields:    Translation:Humans
  141. Olumi AF, Garnick MB, Renshaw AA, Benson CA, Richie JP. Leydig cell hyperplasia mimicking testicular neoplasm. Urology. 1996 Oct; 48(4):647-9. PMID: 8886077.
    Citations:    Fields:    Translation:HumansCells
  142. Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CH, Gonzalez-Zulueta M, Nichols PW, Skinner DG, Jones PA. Role of chromosome 9 in human bladder cancer. Cancer Res. 1993 Sep 01; 53(17):4066-70. PMID: 8358736.
    Citations: 28     Fields:    Translation:HumansCells
  143. Spruck CH, Rideout WM, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, et al. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res. 1993 Mar 01; 53(5):1162-6. PMID: 8439962.
    Citations: 30     Fields:    Translation:HumansCells
  144. Rideout WM, Coetzee GA, Olumi AF, Spruck CH, Jones PA. 5-Methylcytosine as an endogenous mutagen in the p53 tumor suppressor gene. Princess Takamatsu Symp. 1991; 22:207-19. PMID: 1844242.
    Citations:    Fields:    Translation:HumansAnimals
  145. Olumi AF, Skinner EC, Tsai YC, Jones PA. Molecular analysis of human bladder cancer. Semin Urol. 1990 Nov; 8(4):270-7. PMID: 1980959.
    Citations: 5     Fields:    Translation:Humans
  146. Olumi AF, Tsai YC, Nichols PW, Skinner DG, Cain DR, Bender LI, Jones PA. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res. 1990 Nov 01; 50(21):7081-3. PMID: 2208176.
    Citations: 32     Fields:    Translation:HumansCells
  147. Rideout WM, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science. 1990 Sep 14; 249(4974):1288-90. PMID: 1697983.
    Citations: 160     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Olumi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (417)
Explore
_
Co-Authors (69)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.